神经调控市场－全球产业规模、份额、趋势、机会及预测（按类型、应用、区域及竞争格局划分，2021-2031年）

全球神经调控市场预计将从 2025 年的 74.1 亿美元成长到 2031 年的 104.8 亿美元，复合年增长率为 5.95%。

该领域涵盖旨在透过直接向神经输送药物或进行电刺激来改变生物活性并达到治疗效果的医疗技术。推动该领域发展的主要因素是全球人口老化和帕金森氏症等慢性疾病的日益增多，这些疾病需要有效的非鸦片类镇痛策略。根据世界卫生组织（WHO）2024年的数据，全球有超过30亿人患有神经系统疾病，使这些疾病成为全球残疾的主要原因。这凸显了此类医疗干预措施的巨大潜在患者群体。

然而，市场成长面临许多障碍，包括设备成本高昂以及专业医疗基础设施取得方面的不均衡。严格的法规环境和有限的报销选择往往阻碍病人就医，这在资源匮乏的发展中地区尤其普遍。这种不均衡在医护人员中尤为突出，严重限制了医疗服务能力。根据世界卫生组织（世卫组织）2024年的统计数据，高所得国家每10万居民的神经科医生数量是低收入国家的70倍之多，这极大地限制了医疗服务在服务不足地区的市场渗透。

市场驱动因素

新一代神经调控设备的快速技术进步正在改变医疗保健格局，显着提升治疗精准度和病患疗效。製造商致力于将感测功能与封闭回路型系统集成，该系统能够根据即时神经反馈调整刺激，从而克服电池寿命和疗效方面的传统挑战。近期监管的成就也印证了这个趋势，进一步凸显了感测功能的临床价值。例如，在2024年1月的新闻稿《美敦力公司首款Percept RC DBS系统获FDA核准》中，美敦力宣布其能够采集脑波讯号以进行个人化治疗的深部脑部刺激系统获得FDA核准。这些创新使得治疗性介入更加精准，减少了手动调整的需要，从而显着提升了长期运动障碍患者的照护品质。

此外，主要市场参与者不断增加研发投入是推动市场成长的次要因素，透过策略整合加速商业化进程并扩大产品组合。主要企业正积极收购专业公司，以拓展微创治疗方案，并在荐骨神经调控等高成长领域取得竞争优势。正如2024年1月波士顿科学公司宣布收购Axonics时所揭露，该公司已同意以约37亿美元的股票以金额为准收购这家医疗科技公司。这项大规模投资显示了业界对生物电子医学长期盈利的信心。此外，美敦力公司在2024年5月宣布，其神经科学产品组合在该财年的全球销售额将达到94亿美元，这进一步印证了当前市场的庞大规模和商业性可行性。

市场挑战

昂贵的医疗设备和严格的报销政策是限制全球神经调控市场发展的主要阻碍因素。由于保险公司将这些治疗方法归类为「研究性」疗法，或要求提供大量证据证明其医疗必要性才能获得核准，製造商难以获得广泛的医疗覆盖范围。这一经济障碍极大地限制了目标患者群体，因为没有全面保险的个人无法承担植入和后续维护这些系统所带来的高昂自付费用。

医疗服务提供者的支付标准降低，进一步加剧了经济负担，抑制了先进疼痛管理技术的应用。复杂手术报销额的减少，也阻碍了医疗机构对必要人员和设备的投入。根据美国麻醉医师协会2024年11月发布的公告，政府最终确定的明年医疗费用修订方案将使医生服务的报销额降低2.83%，这一变化威胁到提供介入性疼痛治疗​​的诊所的生存。这些财务限制直接阻碍了神经调控解决方案在医疗产业的广泛应用。

市场趋势

脑机介面（BCI）技术的发展是一项重大趋势，它能够帮助患者恢復言语和运动功能，使该领域从单纯的症状管理转向功能重建。研发人员正优先开发可植入式系统，该系统能够解码神经讯号，使瘫痪患者能够操作数位设备，从而满足神经復健领域一项重要的未满足需求。新型血管内系统的安全性和有效性已在临床上得到验证，这为上述进展提供了有力支持。例如，Synchron公司于2024年9月发布的COMMAND研究结果显示，其永久性BCI植入达到了主要安全性终点，在为期12个月的研究期间，6名患者均未发生与设备相关的严重不利事件。这些发现表明生物电子工程技术已显着成熟，并确立了BCI作为帮助瘫痪患者恢復独立生活能力的极具前景的领域的地位。

同时，治疗应用正显着扩展至精神健康领域，尤其是在难治性精神疾病方面。在医疗服务提供者对治疗强迫症和忧郁症的有效非药物疗法的需求推动下，经颅磁刺激 (TMS) 等非侵入性技术正迅速走向商业化。这种广泛应用也体现在专业神经刺激公司强劲的财务表现上。例如，BrainsWay 在 2024 年 11 月发布的「2024 财年第三季财报」中显示，其季度营收为 1,050 万美元，年增 26%，这主要得益于其深部 TMS 系统需求的激增。这一趋势表明，该行业已成功实现向高价值精神疾病领域的多元化发展，并减少了对传统疼痛管理和运动障碍治疗收入的依赖。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球神经调控市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（内部神经调节（脊髓刺激、深部脑刺激、迷走神经刺激、荐椎神经刺激、胃电刺激）、外部神经调节（经皮神经电刺激（TENS）、经颅磁刺激（TMS）、呼吸电刺激（RES）））
  • 依应用方式（脊髓刺激、深部脑部刺激、荐椎神经刺激、迷走神经刺激、胃电刺激、经皮神经电刺激、经颅磁刺激、呼吸电刺激）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美神经调控市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲神经调控市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区神经调控市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲神经调控市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲神经调控市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球神经调控市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Medtronic PLC
• NanoGen Healthcare Pvt. Ltd.
• Boston Scientific Corporation
• Abbott Laboratories Ltd.
• Livanova plc
• Nevro Corporation
• Neurosigma PLC.
• Neuropace, INC.
• Soterix Medical Inc.
• Aleva Neurotherapeutics SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Neuromodulation Market is projected to expand from USD 7.41 Billion in 2025 to USD 10.48 Billion by 2031, reflecting a CAGR of 5.95%. This sector encompasses medical technologies designed to alter biological activity for therapeutic gain by delivering pharmaceutical agents or electrical stimulation directly to nerves. Growth is largely fueled by an aging global demographic and the increasing incidence of chronic conditions like Parkinson's disease, which necessitates effective non-opioid pain management strategies. Data from the World Health Organization in 2024 revealed that over 3 billion individuals globally suffer from neurological conditions, establishing these ailments as the primary cause of disability worldwide and underscoring the massive potential patient base for these medical interventions.

However, market growth faces substantial hurdles related to the prohibitive costs of devices and unequal access to specialized medical infrastructure. Strict regulatory environments and limited reimbursement options frequently hinder patient access, a widespread issue in resource-constrained developing regions. This inequality is particularly evident in the workforce, severely restricting care delivery capabilities. According to 2024 World Health Organization statistics, high-income nations benefit from up to 70 times more neurological professionals per 100,000 residents compared to low-income countries, a discrepancy that significantly blocks widespread market adoption in underserved areas.

Market Driver

Rapid technological progress in next-generation neuromodulation devices is transforming the therapeutic environment by improving precision and patient results. Manufacturers are focusing on integrating sensing capabilities and closed-loop systems that adapt stimulation based on real-time neural feedback, thereby resolving earlier issues related to battery life and efficacy. This trend is highlighted by recent regulatory achievements that confirm the clinical value of sensing-enabled features; for instance, Medtronic announced in a January 2024 press release titled 'Medtronic First-of-its-Kind Percept RC DBS System Receives FDA Approval' that it secured approval for a deep brain stimulation system capable of capturing brain signals for personalized treatment. Such innovations enable more precise interventions, lessening the need for manual adjustments and greatly enhancing care quality for patients managing long-term movement disorders.

Additionally, increased research and development spending by major market players serves as a secondary driver, accelerating commercialization and portfolio growth through strategic consolidation. Leading corporations are aggressively acquiring specialized companies to expand their minimally invasive options and gain a competitive edge in high-growth areas such as sacral neuromodulation. As reported in the 'Boston Scientific to Acquire Axonics, Inc.' announcement in January 2024, Boston Scientific agreed to purchase the medical technology firm for an equity value of roughly $3.7 billion. This significant investment demonstrates industry confidence in the long-term profitability of bioelectronic medicine, further evidenced by Medtronic's report in May 2024 that its Neuroscience Portfolio achieved $9.4 billion in global revenue for the fiscal year, showcasing the immense scale and commercial viability of the current market.

Market Challenge

The combination of high device costs and restrictive reimbursement policies represents a major constraint on the global neuromodulation market. Manufacturers struggle to obtain broad insurance coverage because payers frequently label these therapies as investigational or demand extensive proof of medical necessity prior to authorization. This financial obstacle severely restricts the addressable patient population, as individuals lacking comprehensive insurance cannot sustain the significant out-of-pocket costs associated with the implantation and ongoing maintenance of these systems.

This economic strain is exacerbated by cuts in payment rates for healthcare providers, which discourage the utilization of advanced pain management methods. When reimbursement for performing complex procedures declines, medical facilities are less inclined to invest in essential personnel or equipment. According to the American Society of Anesthesiologists in November 2024, the government's finalized fee schedule for the upcoming year introduced a 2.83 percent reduction in reimbursement for physician services, a change that jeopardizes the financial viability of practices providing interventional pain therapies. Such fiscal constraints directly impede the scalability of neuromodulation solutions within the healthcare industry.

Market Trends

The evolution of Brain-Computer Interface (BCI) technologies for speech and motor restoration marks a crucial trend, shifting the sector from simple symptom management to functional recovery. Developers are prioritizing implantable systems that decode neural signals to allow paralyzed patients to operate digital devices, addressing critical unmet needs in neurorehabilitation. This advancement is supported by successful clinical outcomes regarding the safety and efficacy of new endovascular systems; specifically, Synchron announced in its 'COMMAND Study Results' in September 2024 that its permanent BCI implant achieved its primary safety endpoint with no serious device-related adverse events across six patients during a 12-month study. These findings indicate a significant maturation in bioelectronic engineering, establishing BCI as a promising future sector for restoring independence to those with paralysis.

Simultaneously, the market is undergoing significant broadening of therapeutic applications into mental health, especially for treatment-resistant psychiatric disorders. Non-invasive techniques like Transcranial Magnetic Stimulation (TMS) are seeing rapid commercial uptake as providers look for effective, non-pharmaceutical options for obsessive-compulsive disorder and depression. This increasing adoption is mirrored in the strong financial performance of specialized neurostimulation firms; for example, BrainsWay reported in its 'Third Quarter 2024 Financial Results' in November 2024 that quarterly revenue rose 26 percent year-over-year to $10.5 million, fueled largely by surging demand for its Deep TMS systems. This trend underscores the industry's successful diversification into high-value psychiatric segments, lessening its dependence on revenue from traditional pain management and movement disorders.

Key Market Players

• Medtronic PLC
• NanoGen Healthcare Pvt. Ltd.
• Boston Scientific Corporation
• Abbott Laboratories Ltd.
• Livanova plc
• Nevro Corporation
• Neurosigma PLC.
• Neuropace, INC.
• Soterix Medical Inc.
• Aleva Neurotherapeutics SA

Report Scope

In this report, the Global Neuromodulation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuromodulation Market, By Type

• Internal Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation)
• External Neuromodulation(Transcutaneous Electrical Nerve Stimulation (TENS), Transcranial Magnetic Stimulation (TMS), Respiratory Electrical Stimulation (RES))

Neuromodulation Market, By Application

• Spinal Cord Stimulation
• Deep Brain Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Gastric Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

Neuromodulation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuromodulation Market.

Available Customizations:

Global Neuromodulation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuromodulation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Internal Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation), External Neuromodulation(Transcutaneous Electrical Nerve Stimulation (TENS), Transcranial Magnetic Stimulation (TMS), Respiratory Electrical Stimulation (RES)))
  • 5.2.2. By Application (Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Gastric Electrical Stimulation, Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation, Respiratory Electrical Stimulation)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Neuromodulation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neuromodulation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Neuromodulation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Neuromodulation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Neuromodulation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neuromodulation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Neuromodulation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Neuromodulation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Neuromodulation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Neuromodulation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Neuromodulation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neuromodulation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Neuromodulation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Neuromodulation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Neuromodulation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Neuromodulation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Neuromodulation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Neuromodulation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Neuromodulation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Neuromodulation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Neuromodulation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neuromodulation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Neuromodulation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Neuromodulation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neuromodulation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. NanoGen Healthcare Pvt. Ltd.
• 15.3. Boston Scientific Corporation
• 15.4. Abbott Laboratories Ltd.
• 15.5. Livanova plc
• 15.6. Nevro Corporation
• 15.7. Neurosigma PLC.
• 15.8. Neuropace, INC.
• 15.9. Soterix Medical Inc.
• 15.10. Aleva Neurotherapeutics SA

16. Strategic Recommendations

17. About Us & Disclaimer